AbbVie Inc (ABBV) : Woodford Investment Management Llp scooped up 2,269,300 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 15, 2016. The investment management firm now holds a total of 11,063,300 shares of AbbVie Inc which is valued at $658,376,983.AbbVie Inc makes up approximately 28.40% of Woodford Investment Management Llp’s portfolio.
AbbVie Inc opened for trading at $60.57 and hit $61.43 on the upside on Wednesday, eventually ending the session at $61.37, with a gain of 1.47% or 0.89 points. The heightened volatility saw the trading volume jump to 57,02,353 shares. Company has a market cap of $98,882 M.
Other Hedge Funds, Including , Mission Wealth Management boosted its stake in ABBV in the latest quarter, The investment management firm added 173 additional shares and now holds a total of 10,363 shares of AbbVie Inc which is valued at $616,702. AbbVie Inc makes up approx 0.16% of Mission Wealth Management’s portfolio.Stonebridge Capital Management Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 2,000 additional shares and now holds a total of 17,733 shares of AbbVie Inc which is valued at $1,055,291. AbbVie Inc makes up approx 0.45% of Stonebridge Capital Management Inc’s portfolio.Beese Fulmer Investment Management reduced its stake in ABBV by selling 1,400 shares or 7.43% in the most recent quarter. The Hedge Fund company now holds 17,439 shares of ABBV which is valued at $1,037,795. AbbVie Inc makes up approx 0.30% of Beese Fulmer Investment Management’s portfolio.Creative Planning reduced its stake in ABBV by selling 2,417 shares or 1.26% in the most recent quarter. The Hedge Fund company now holds 189,027 shares of ABBV which is valued at $11,058,080. AbbVie Inc makes up approx 0.09% of Creative Planning’s portfolio.
On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.